Navigation Links
BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
Date:10/12/2007

d-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that the pivotal trial with forodesine HCL in CTCL may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCL in both T-ALL and CTCL may not be successful, that we may not resolve satisfactorily the particulate matter issue with the intravenous formulation of forodesine HCL, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future clinical trials may not have positive results, that we may not be able to complete successfully the Phase IIb trials for forodesine HCL that are currently planned to be pivotal, that we may not be able to announce preclinical developments for additional compounds by year-end 2007 as currently proposed, that we or our licensees may not be able to continue future development of our current and future development programs, that our development
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
2. Malvern initiates European user group meetings for chemical imaging
3. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
4. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
5. Celsion Completes Enrollment in Phase I Liver Cancer Study
6. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
11. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... BEDFORD, Mass. , Sept. 2, 2014  Hologic, Inc. (NASDAQ: ... , President and Chief Executive Officer, will present at the ... City , New York on ... Interested parties are invited to listen to the live ... Hologic,s website at www.hologic.com/investors-overview . An archive of the ...
(Date:9/2/2014)... 2, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... Drug Administration (FDA) has granted orphan drug status to ... "The FDA Office of Orphan Products Development ... to identify and designate drug candidates that could potentially ... development of such products," said Craig M. Audet ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 /PRNewswire/ ... announced the submission of a Marketing Authorization ... (EMA) via the centralized procedure for talimogene ... adults with melanoma that is regionally or ... immunotherapy administered as an intralesional injection that ...
Breaking Medicine Technology:Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 6
... LAKES, N.J. , May 11 Nearly ... (LABAs) alone, and not in combination with other asthma ... and Drug Administration (FDA) on the risk of worsening ... according to a new study from the Medco ...
... May 11 Ethicon Endo-Surgery ... of surgical devices, the HARMONIC FOCUS® Long Curved Shears, ... that require deep access. The HARMONIC FOCUS® Long Curved ... using precise ultrasonic energy that minimizes thermal damage to ...
Cached Medicine Technology:Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 2Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 3Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 4Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 5Ethicon Endo-Surgery Introduces HARMONIC FOCUS(R) Long Curved Shears for Deep Surgical Access 2
(Date:9/2/2014)... (PRWEB) September 02, 2014 According ... http://www.idataresearch.com ), the leading global authority in medical ... market is expected to grow to over ... by an increase in the number of procedures ... kidney stones. This market includes TURP devices, laser ...
(Date:9/2/2014)... York (PRWEB) September 02, 2014 ... of nanotechnology in diagnosing, treating and/or prevention of ... applied for treating cardiovascular, neurological, and oncology diseases. ... of knowledge pertaining to various nanoparticles, their medical ... There still exists considerable scope for research in ...
(Date:9/2/2014)... Dallas, TX (PRWEB) September 02, 2014 On ... annual family health and fitness fair ¡Vive tu vida! Get ... and good nutrition for better health and wellness for people ... free and open to the public, will be held at ... from 8:00 am to 1:00 pm. , “Since 2007, ...
(Date:9/2/2014)... 2014 Durable Medical Goods manufacture ... leasing and financing company LeaseQ, Inc. to help customers ... Since late 2012, LeaseQ’s breakthrough finance shopping platform has ... they need to run their business. , Said ... enable the ThermoTek sales team to provide customers faster ...
(Date:9/2/2014)... 02, 2014 The American Healthcare Documentation ... Free-Tuition Guarantee for its ICD-10 Medical Coding Bridge Program. ... highest level of confidence to students who are seeking ... but are faced with the uncertainty brought on by ... ICD-10 until October 1st, 2015. , AHDPG’s Free-Tuition Guarantee ...
Breaking Medicine News(10 mins):Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Technology Manufacturer ThermoTek Announces New Partnership with LeaseQ.com to Help More Customers Acquire Equipment Faster and Cheaper 2Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 2Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 3
... January is Thyroid Awareness Month , JACKSONVILLE, Fla. , ... and feel our best. Yet many never realize that one of ... just below the neck.   , The thyroid is a small, ... affect the function of many of the body,s organs including the ...
... 2010 - Chronic and severely stressful situations, like those ... associated with smaller volumes in "stress sensitive" brain regions, ... and the hippocampus, a brain region involved in memory ... Biological Psychiatry , suggests that chronic insomnia may ...
... 27, 2010) Researchers at Tufts University School of Medicine ... have developed a new tool for gene therapy that significantly ... other carriers and DNA alone, according to a study published ... Medicine . The tool, a peptide called PEG-POD, provides a ...
... to delay lactation in new moms, researchers find , ... class of antidepressants can cause delayed lactation in new ... order to breast-feed their babies, a new study says. ... reuptake inhibitors (SSRIs), which include such drugs as Prozac ...
... ... ... recognition of cervical cancer awareness month, Debra Macki , one of the industry’s most ... of this preventable cancer. The palette includes three shades that represent the three tools women ...
... ... Payment Platform for Utah’s Answer to Health Care Reform , ... Salt Lake City, UT (Vocus) January 27, ... by the State of Utah to provide payment-processing solutions and HSA administration for the ...
Cached Medicine News:Health News:Unlocking the Secrets to a Healthier Body 2Health News:Unlocking the Secrets to a Healthier Body 3Health News:Losing sleep, losing brain? 2Health News:Researchers develop new tool for gene delivery 2Health News:Antidepressants May Complicate Breast-Feeding 2Health News:Celebrity Make-Up Artist Introduces New Eye Shadow Palette for Cervical Cancer Awareness 2Health News:Celebrity Make-Up Artist Introduces New Eye Shadow Palette for Cervical Cancer Awareness 3Health News:HealthEquity Partners with State of Utah to Launch Pilot of Utah Health Exchange 2Health News:HealthEquity Partners with State of Utah to Launch Pilot of Utah Health Exchange 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: